We have constructed a plasmid that, when introduced into Escherichia coil, induces the synthesis of large quantities of a protein with an apparent molecular mass of 66 kDa that differs from human immunodeficiency virus (HIV) RNA-dependent DNA polymerase (deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase or reverse transcriptase, EC 2.7.7.49) only in that it has two additional aminoterminal amino acids. This protein is soluble in E. coli extracts, is active in reverse transcriptase assays, and shows inhibition profiles with dideoxy-TTP and dideoxy-GTP that are indistinguishable from the viral enzyme. The deletion of 23 amino-terminal or carboxyl-terminal amino acids or the insertion of 5 amino acids at position 143 substantially decreases the polymerizing activity of the HIV reverse transcriptase made in E. coli. The properties of a 51-kDa reverse transcriptaserelated protein made in E. coli suggests that the p51 found in the virion probably does not have substantial polymerizing activity. The full-length HIV reverse transcriptase and the various mutant proteins produced in E. coli should be quite useful for structural and biochemical analyses as well as for the production of antibodies. In the virion, the reverse transcriptase is released from a larger polypeptide precursor by proteolytic cleavage (1). To permit the expression of the free HIV reverse transcriptase, we have taken the viral segment encoding the reverse transcriptase and modified the region at the ends of this segment so that there are initiation and termination codons at the positions where proteolytic cleavage takes place. The modified segment was introduced into an Escherichia coli expression plasmid. When introduced into E. coli, the plasmid with the HIV reverse transcriptase insert induces the synthesis of a large amount (several percent of the total E. coli protein) of soluble, enzymatically active, HIV reverse transcriptase. We show here that the ability of the HIV reverse transcriptase produced in E. coli to be inhibited by the dideoxy analogs of thymidine and guanosine is identical to the inhibition of virion reverse transcriptase. To study the catalytic domains of the HIV reverse transcriptase, we have begun a mutagenic analysis of this enzyme using the E. coli system. The E. coli-produced HIV polymerase can be used to search for inhibitors, to facilitate structural and biochemical studies, and to produce both monoclonal and polyclonal antibodies.
polymerase (deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase or reverse transcriptase, EC 2.7.7.49), that is responsible for copying the RNA genome found in the virion into DNA. This copying of viral RNA into DNA is an obligate step in the viral life cycle, and the DNA copy is subsequently inserted into the genome of the infected cell (1) . No cellular homolog of viral reverse transcriptases has been discovered, although many normal cells carry endogenous retroviruses and retrotransposons that encode reverse transcriptases. The viral reverse transcriptase is, for this reason, a potential target for drug therapies designed to interfere with the life cycle of retroviruses, most notably the human immunodeficiency virus (HIV) (2) (3) (4) (5) (6) (7) (8) (9) . The drug 3'-azido-3'deoxythymidine (also called "AZT") is an effective anti viral agent presumably because the derivative triphosphate is recognized as thymidine triphosphate by HIV reverse transcriptase (4) (5) (6) . Only small amounts of reverse transcriptase are found in virions, and the search for drugs that would interrupt the HIV viral life cycle by interfering with reverse transcription would be facilitated by a better source of the HIV enzyme.
In the virion, the reverse transcriptase is released from a larger polypeptide precursor by proteolytic cleavage (1) . To permit the expression of the free HIV reverse transcriptase, we have taken the viral segment encoding the reverse transcriptase and modified the region at the ends of this segment so that there are initiation and termination codons at the positions where proteolytic cleavage takes place. The modified segment was introduced into an Escherichia coli expression plasmid. When introduced into E. coli, the plasmid with the HIV reverse transcriptase insert induces the synthesis of a large amount (several percent of the total E. coli protein) of soluble, enzymatically active, HIV reverse transcriptase. We show here that the ability of the HIV reverse transcriptase produced in E. coli to be inhibited by the dideoxy analogs of thymidine and guanosine is identical to the inhibition of virion reverse transcriptase. To study the catalytic domains of the HIV reverse transcriptase, we have begun a mutagenic analysis of this enzyme using the E. coli system. The E. coli-produced HIV polymerase can be used to search for inhibitors, to facilitate structural and biochemical studies, and to produce both monoclonal and polyclonal antibodies.
MATERIALS AND METHODS
Bacteria and Plasmids. E. coli strain DH5 (a derivative of DH-1, see ref. 10 ) was used as a recipient for DNA transformations (frozen competent cells were purchased from Bethesda Research Laboratories). The HIV DNA polymerase gene constructs were derived from the HIV proviral clone BH10 (11) . The construction of the plasmid is given in detail in Fig. 1 . E. coli DH5 cells transformed with the various plasmids were grown in NZYM liquid broth (25) supplemented with 100 Ag of ampicillin per ml.
Virus. Twice-banded HIV-H9 was obtained from Program Resources, Frederick, MD (batch p2627).
Bacterial and Viral Lysis. The bacteria containing either plasmids that express HIV reverse transcriptase or the parental plasmid pUC12N were grown for 12-16 hr with shaking at 370C. Bacteria were collected by centrifugation in a Microfuge for 2 min at 10,000 rpm, and the pellet was washed once with cold 100 mM NaCl/20 mM Tris chloride/i mM EDTA, final pH 7.4 (TSE buffer). Bacteria Polyacrylamide Gel Electrophoresis. Ten percent polyacrylamide gels containing 0.1% NaDodSO4 were prepared and subjected to electrophoresis as described (12) . Bacteria were grown in NZY broth and collected by centrifugation. The pellets were disrupted in gel sample buffer (1% NaDodSO4/1% 2-mercaptoethanol/10% glycerol/50 mM Tris chloride, pH 6.8/10 ug of bromphenol blue per ml) for 2 min at 100TC. Gels were stained with 0.1% Coomassie brilliant blue. In most cases, the protein from 60 til of bacterial culture was loaded on each gel slot.
Gel Filtration of Lysed Bacteria. The soluble bacterial proteins (prepared as described above for reverse transcriptase assay) were passed over Sephadex G-25 columns to remove potential inhibitors of the enzymatic activity. The supernatants from the bacterial lysates were loaded at 40C on Sephadex G-25 columns preequilibrated with 0.2 M NaCl/2 mM dithiothreitol/0.2% Triton X-100/20% glycerol/25 mM Tris chloride, pH 7.4. After loading, the columns were washed with the same preequilibration buffer, and the fractions were assayed both for reverse transcriptase activity and for protein concentration. The main peak of enzymatic activity trails the main protein peak. Samples from the most active fractions were used for further analysis and for monitoring the effects of inhibitors. The reverse transcriptase activity recovered from the columns was 10-15 times higher than the activity that was loaded, indicating removal of inhibitors, although there was no substantial increase in the enzyme purity relative to bacterial proteins, as judged from polyacrylamide gel electrophoresis of the samples.
RESULTS

Introduction of Initiation and Termination
Sites into the HIV Reverse Transcriptase Gene. Since the HIV reverse transcriptase is normally produced by proteolytic cleavage of the gag-pol polyprotein, the portion of the HIV genome encoding reverse transcriptase does Apt-begin with an initiation codon, nor does it end with a terihination codon (1, 11, 13, 14) . Before the enzyme can be produced in E. coli, an appropriate initiation codon and termination codon must be introduced into the gene. The procedure is described in detail in Fig. 1 . Briefly, restriction sites were chosen that lie just inside the HIV reverse transcriptase domain. Synthetic DNA segments were made that replaced both the segment of the gene encoding the amino-and carboxyl-terminal portion of the HIV reverse transcriptase. The segment that replaces the portion of the gene encoding the carboxyl terminus provides a termination codon at precisely the site where proteolytic cleavage takes place (see Fig. 1 ; see also ref. 15 ). The carboxyl terminus of the reverse transcriptase is inferred from the known amino terminus of the "integrase" and from the knowledge that for other retroviruses there is no gap between the carboxyl terminus of the reverse transcriptase and the amino terminus of the integrase (1). The synthetic DNA encoding the amino terminus of the HIV reverse transcriptase provides an initiation codon. Protein synthesis initiates with methionine and, to facilitate the constructions, the initiator methionine codon was incorporated into the recognition site for the restriction enzyme Nco I, which is CCATGG. In order to retain the ability to excise the HIV reverse transcriptase coding region for other constructions (see Discussion), we used a synthetic DNA segment that not only could be ligated to an Nco I site but also after ligation would recreate the Nco I site. However, the last base of the Nco I site (guanosine) defines the first base of the second codon. Because the first amino acid of the mature HIV reverse transcriptase is a proline, it is impossible both to recreate the Nco I site and to encode proline as the second amino acid. Given these facts, we have elected to add two amino acids to the amino terminus of the HIV reverse transcriptase, an amino-terminal methionine and a valine as the second amino acid and then to continue with the proline. In some cases, E. coli removes one or two amino-terminal amino acids from primary translation prod- ucts. We have not yet directly examined the amino terminus of the protein that accumulates in E. coli.
The coding region for the HIV reverse transcriptase was ligated into the pUC plasmid pUC12N, which differs from pUC12 only in that the lacZ initiator ATG has been converted by site-directed mutagenesis to an Nco I site (refs. 16 and 17; see Fig. 1 ). The recombinant plasmid was introduced into E. coli strain DH5, and colonies were chosen that were shown to contain the internal segment deriving from HIV reverse transcriptase and the two synthetic DNA segments (see Materials and Methods).
Expression of the HIV Reverse Transcriptase in E. coli. Colonies containing the appropriate plasmid were grown in NZY broth and harvested by centrifugation. The bacterial pellets were disrupted directly in gel sample buffer, and the proteins were analyzed by NaDodSO4/polyacrylamide gel electrophoresis. The pUC12N plasmid carrying the complete HIV reverse transcriptase coding region induced the synthesis of a protein of :66 kDa (see Fig. 2 As a control for the inhibition of the HIV reverse transcriptase, we also tested the inhibitors on Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase synthesized in E. coli (A.H. and S.H.H., unpublished data), which also was fractionated on G-25. The HIV reverse transcriptase made in E. coli and the HIV reverse transcriptase from the virions responded identically to increasing amounts of dideoxy-GTP or dideoxy-TTP (Fig. 3) . The Mo-MuLV polymerase responded differently, particularly to dideoxy-TTP. The HIV enzyme was much more sensitive to dideoxy-TTP than was the Mo-MuLV enzyme (see Fig. 3 proteins that are found in large quantity in the E. coli lysates. By substituting a different synthetic DNA for the Nco I-Bal I segment, it was possible to synthesize an HIV reverse transcriptase protein that lacks the first 23 amino acids of the virion enzyme (although it does retain the methionine and the additional valine required to reconstruct the Nco I site). This protein was made in quantities comparable to the full-length enzyme; however, it had no detectable polymerizing activity (see Table 2 ). Three carboxyl-terminal mutants that make substantial amounts of protein were constructed by altering the carboxyl-terminal synthetic DNA segment: one lacks the last 8 amino acids, one lacks 16 amino acids, and the third lacks 23 amino acids. Although the 8-and the 16-amino acid deletions caused slightly less activity than the full-length protein did, the strains that made these proteins appeared to contain slightly less of the deleted products than the strain that made the wild-type enzyme (see Fig. 2 ). By contrast, the deletion of the carboxyl-terminal 23 amino acids dramatically decreased the polymerizing activity of the protein product (see Table 2 ).
We also made three different insertions at the unique EcoRV site (position 2556). These led to the synthesis of a protein that had lost a tyrosine at amino acid position 143 (measured from the amino terminus of the viral enzyme) and had an insertion of 5 amino acids at this position. Although the three insertions had substantially different sequences, the insertions all led to the production of proteins that lacked polymerizing activity. An insertion at the unique PflMI site (position 3065) led to the loss of two amino acids at amino acid position 313 and the insertion at this position offive new amino acids. In contrast to the EcoRV mutant products, the 43 HIV RT constructs in E. coli were assayed for RT activity in bacterial extracts as described. The various clones are named for the mutations they express: CT, deletions from the carboxyl terminus of the molecule followed by the number of amino acids deleted; NT, deletions from the amino acid terminus of the reverse transcriptase followed by the number of amino acids deleted; RV, three different insertions, each of 5 amino acids, at amino acid position 143 (DNA insertion in the EcoRV site); and PM, a substitution of 5 amino acids for two at amino acid position 313 (DNA insertion at the PflMI site).
The specific sequences for each of the mutant proteins are as follows: wild-type has, compared with the virion enzyme, two additional amino-terminal amino acids, Met-Val; CT-133 has 133 amino acids deleted from the carboxyl terminus, and the last 11 amino acids derive from the + 1 reading frame, giving a sequence Leu-Trp-Tyr-Gln-His-Thr-Lys-Glu-Leu-Glu-Glu-Met-Asn-Lys at the carboxyl terminus; CT-23 ends Tyr-Leu-Ala-Trp-Val-Leu; CT-16 ends His-Lys-Gly-Ile-Gly-Gly; CT-8 ends Asp-Lys-Leu-Val; AT-23 has a deletion of 23 amino-terminal amino acids but still has the two extra amino acids (Met-Val) present in the wild-type enzyme, hence the sequence begins with Met-Val-Trp-Pro-Leu-Thr; RV-1,2,3 have DNA insertions equivalent to 5 amino acids (italic) in the EcoRV site (Gly-Ile-Arg-Tyr-Gln-Tyr-Asn), giving Gly-lle-ArgLeu-Gly-Ala-Pro-Asn-Gln-Tyr-Asn (RV-1), Gly-Ile-Arg-Trp-ArgAla-Arg-His-Gln-Tyr-Asn (RV-2), and Gly-Ile-Arg-Ser-Asp-AlaSer-Asp-Gln-Tyr-Asn (RV-3); and PM-1 has Glu-Pro-Leu-Gly-AlaPro-Asn-Gly-Val instead of Glu-Pro-Val-His-Gly-Val.
product of the PflMI mutation retained approximately half the activity of the wild-type protein (see Table 2 ).
We also asked whether the 51-kDa reverse transcriptaserelated molecule found in virions has enzymatic activity. Since the 51-kDa protein found in virions has the same amino terminus as the 66-kDa enzyme, it is likely that the 51-kDa protein lacks the carboxyl terminus of the 66-kDa protein (18) . Based on this assumption, we made a construction that would induce the synthesis of the amino-terminal 70%o of the HIV reverse transcriptase molecule. This strain did not produce substantial amounts of enzyme; however, we did find that, by deleting the Kpn I-Kpn I segment from the wild-type construction, E. coli would synthesize large amounts of a 51-kDa protein. This protein lacks the last 133 amino acids of the 66-kDa enzyme; however, since the Kpn I-Kpn I deletion induced a frameshift, 11 unrelated amino acids were added to the carboxyl terminus. This protein had little, if any, polymerizing activity (see Table 2 ). There are several purposes behind synthesizing the HIV reverse transcriptase in E. coli. The E. coli-synthesized reverse transcriptase is soluble, enzymatically active, produced in large amounts and, when analyzed with two inhibitors, dideoxy-TTP and dideoxy-GTP, has properties indistinguishable from the viral enzyme. The E. coli enzyme should be useful for the preliminary screening of drugs in vitro, although it will not replace replication assays in cultured cells. However, there is one caveat: most of the substrate analogs should be tested in the in vitro reverse transcriptase assay in the form of triphosphates; to be used as drugs, the analogs would be given as free nucleotides or nucleosides.
DISCUSSION
In addition to being a tool for testing drugs directly, the E. coli enzyme should be a convenient source for preparing large quantities of the enzyme for biochemical and physical analyses, including x-ray structure determination. If the structure of the enzyme were known in detail, it might be possible to use this detailed structure to design drugs that would specifically inhibit the enzyme. The E. coli enzyme also is being used for the preparation of both monoclonal and polyclonal antibodies. Finally, it should be possible to use the E. coli system as a tool to explore the limits imposed on the function of the HIV reverse transcriptase by its primary sequence. This can be explored in several ways. Naturally occurring variants of the HIV reverse transcriptase could be produced in E. coli in the same fashion, and their physical and biochemical properties could be compared. In addition, other less-related reverse transcriptases can be expressed by using the same system. We already have expressed the Mo-MuLV reverse transcriptase and demonstrated that, with respect to inhibitors, it has properties distinct from the HIV enzyme. Finally, we have begun to make mutations in the HIV reverse transcriptase. The analyses of such mutations should, coupled with biochemical and structural studies, not only provide information on the relationship between the primary sequence and the catalytic activity of the enzyme but also should help to define the limits of variability that will be encountered in the reverse transcriptase of different HIV isolates.
